A dose-ranging study of selegiline in pa
β
Nathalie Andreu; Christine Damase-Michel; Jean-Michel Senard; Olivier Rascol; Pr
π
Article
π
1997
π
John Wiley and Sons
π
English
β 337 KB
π 1 views
## Abstract A doseβranging study of selegiline was performed in patients with Parkinson's disease to determine the minimal dosage of the drug able to inhibit β₯95% of platelet monoamine oxidase (MAO) activity. Different doses of selegiline (5 or 10 mg daily, 10 or 20 mg weekly) were studied in four